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Effects of Intravitreal Ranibizumab on Retinal
Hard Exudate in Diabetic Macular Edema
Findings from the RIDE and RISE Phase III Clinical Trials
Amitha Domalpally, MD,1 Michael S. Ip, MD,1 Jason S. Ehrlich, MD, PhD2
Purpose: To evaluate the effect of monthly intravitreal ranibizumab on hard exudate (HE) area and the impact
of HE on visual acuity (VA) outcomes in diabetic macular edema (DME) patients using data from 2 phase III clinical
trials.
Design: Exploratory analyses of phase III, randomized, double-masked, sham-controlled, multicenter clinical
trials.
Participants: Adults with DME, baseline best-corrected VA 20/40 to 20/320 Snellen equivalent, and central
foveal thickness of 275 mm.
Methods: Between the 2 studies, 759 patients with DME were randomized to receive monthly 0.3 or 0.5 mg
intravitreal ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) or sham injections.
Main Outcome Measures: Hard exudate area was assessed from color fundus stereophotographs both on
an ordinal scale and using continuous estimates of areas within the Early Treatment Diabetic Retinopathy Study
grid.
Results: Data from 739 eyes were available for analysis. Mean baseline HE area was similar across treatment
groups, ranging from 0.65 to 0.82 mm2. Through month 24, the percentage of eyes without HE increased from
20.9% to 36.3% in the sham group and from 22.1% to 61.3% and 23.6% to 62.0% in the ranibizumab 0.3-mg
and 0.5-mg groups, respectively. Resolution of HE became apparent sometime after month 6 in ranibizumab-
treated eyes. At baseline, there was no meaningful correlation between VA and presence or absence of HE.
After baseline, there also was no consistent correlation between presence or absence of HE and change in VA
over time.
Conclusions: In this exploratory analysis, monthly intravitreal ranibizumab resulted in signiﬁcantly greater
reduction of HE area compared with sham (P < 0.0001). In contrast to the rapid effects of ranibizumab on
macular edema, changes in HE area were more gradual. Contrary to prior expectations, the presence and area
of HE did not increase as DME resolved (either in the ranibizumab or sham groups). Importantly, baseline VA
was not correlated with presence of HE, nor was the therapeutic beneﬁt of ranibizumab on VA affected
negatively by the presence of HE. These data suggest that in the context of intravitreal antievascular
endothelial growth factor therapy, the presence of HE is not a prognostic indicator of poor visual
outcomes. Ophthalmology 2015;122:779-786 ª 2015 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.Macular edema is a common cause of vision loss in patients
with diabetes who have retinopathy.1,2 Diabetic macular
edema (DME) results from hyperpermeability of retinal
vessels leading to extravasation of ﬂuid and lipoproteins
(hard exudate [HE]) into the retinal layers.3,4 The Early
Treatment Diabetic Retinopathy Study (ETDRS) showed
that retinal HE frequently may be observed along with
macular edema.5 Furthermore, HE at the center of the
macula is associated independently with increased risk of
visual impairment in eyes with macular edema.6 In the
past, it generally has been considered that residual HE
tends to remain or even increase in area after resolution of
edema, regardless of whether the edema resolves 2015 by the American Academy of Ophthalmology.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.spontaneously or with the application of macular laser.7
Additionally, recent studies have shown that intraretinal
microexudate visible on spectral-domain optical coherence
tomography (OCT) accumulates and evolves into clinically
visible HE with reduction in retinal thickness.8,9 Thus, the
resolution of macular edema could result in HE precipitation
in the macula, which in severe cases can evolve into
subretinal ﬁbrosis, with adverse effects on visual function.10
Lipid-lowering agents have been reported to reduce the
risk of vision loss by reducing HE formation.6,11e13 Recent
studies have shown that intravitreal triamcinolone is
effective in reducing HE, although triamcinolone has no
advantage over laser for treatment of DME with regard to779http://dx.doi.org/10.1016/j.ophtha.2014.10.028
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Ophthalmology Volume 122, Number 4, April 2015visual acuity outcomes.14e16 In recent years, intravitreal
therapy with antievascular endothelial growth factor
(VEGF) has emerged as the treatment of choice for DME,
either independently or in combination with macular
laser.17e19 In phase III trials, intravitreal injections of rani-
bizumab (Lucentis; Genentech, Inc., South San Francisco,
CA), an anti-VEGF agent, have been shown to improve
visual acuity in patients with DME, to improve retinal
anatomic features (both macular edema and retinopathy
severity20,21), and to reduce the risk of subsequent vision
loss.22
The purpose of the current analysis was to assess the
effect of intravitreal anti-VEGF therapy on retinal HE in
patients with DME and to assess the impact of retinal HE on
DME treatment outcomes. The timing and degree of reso-
lution and the effect of HE on visual function also were
assessed. Data collected as part of phase III randomized
studies of ranibizumab in patients with center-involved
DME, which included frequently acquired fundus photo-
graphs throughout a 24-month double-masked treatment
period, provides a rich data set for exploration of this topic.Methods
Clinical Trial Design
The RIDE and RISE studies are methodologically identical phase
III, double-masked, sham injection-controlled, randomized clinical
trials of ranibizumab in center-involved DME. Details of the
methodology and key visual acuity and safety ﬁndings have been
described previously.22 Study protocols were approved by
institutional review boards and ethics committees, and
participants provided written informed consent. The 2 completed
studies are registered on clinicaltrials.gov (RIDE identiﬁer,
NCT00473382; and RISE identiﬁer, NCT00473330).
Brieﬂy, individuals 18 years of age or older with decreased
vision resulting from DME (study eye best-corrected visual acuity of
20/40 to 20/320 approximate Snellen equivalent) and central sub-
ﬁeld thickness 275 mm or more on time-domain OCT were eligibleFigure 1. Fundus photographs obtained at (A) baseline and (B) month 24 show
780for enrollment. Study inclusion criteria are detailed elsewhere.22
One eye per patient was randomized to monthly sham injections
or monthly intravitreal injections of 0.3 or 0.5 mg ranibizumab
through month 24. Macular laser was available to all patients per
protocol-speciﬁed criteria, beginning at month 3. Although the
phase III program continued to follow up and treat patients beyond
month 24,23 the data derived from the ﬁrst 24 months of the RIDE
and RISE studies are the focus of this report.
Grading Protocol
Stereoscopic 7-ﬁeld dilated color fundus photographs were
obtained at each patient’s screening visit and at months 3, 6, 12, 18,
and 24. Photographs were evaluated at the University of Wisconsin
Fundus Photograph Reading Center (Madison, WI) by trained
evaluators masked to both treatment assignment and images from
previous visits. Evaluation included assessment of severity of
diabetic retinopathy and features of macular edema. Macular
edema evaluation included a detailed grading of HE within the
modiﬁed ETDRS grid. The presence of HE within the grid and at
the center of the macula was assessed. The area of HE in each
subﬁeld is estimated using standard drusen circles, similar to dru-
sen area assessment.24 Cumulative areas of HE were derived for
the central and inner subﬁelds and for the entire grid (Fig 1).
The ETDRS classiﬁcation based on a set of standard
photographs was used for categorical assessment of HE.5,6 Based
on these standard photographs, the area of HE was classiﬁed as
deﬁnite (>0e0.1 mm2), obvious (>0.1e0.5 mm2), moderate
(>0.5e2.5 mm2), or severe (>2.5 mm2). Reproducibility of HE
evaluation was assessed by periodic re-evaluation of the images
(see details in “Results”).
Statistical Analysis
The percentage of patients with HE was compared across the 3
arms. Cross-tabulations were used to compare change in HE status
over time. For the purposes of this report, a change of 2 steps in the
HE category was considered a clinically signiﬁcant outcome.
Pearson correlation coefﬁcients were used to compare baseline HE
with change in visual acuity. Reproducibility was assessed with
percentage agreement and k statistics for the ordinal scale and
Bland-Altman plots for the area measurements.ing resolution of hard exudate after treatment with intravitreal ranibizumab.
Table 1. Baseline Distribution of Hard Exudate Severity by Early Treatment Diabetic Retinopathy Study Category in Study Eyes
Hard Exudate Severity Category Sham (n [ 253), No. (%)
Ranibizumab, No. (%)
0.3 mg (n ¼ 240) 0.5 mg (n ¼ 246) Pooled (n ¼ 486)
Absent/questionable 53 (20.9) 53 (22.1) 58 (23.6) 111 (22.8)
Deﬁnite (>0e0.1 mm2) 47 (18.6) 49 (20.4) 47 (19.1) 96 (19.8)
Obvious (>0.1e0.5 mm2) 61 (24.1) 58 (24.2) 70 (28.5) 128 (26.3)
Moderate (>0.5e2.5 mm2) 82 (32.4) 73 (30.4) 61 (24.8) 134 (27.6)
Severe (>2.5 mm2) 10 (4.0) 7 (2.9) 10 (4.1) 17 (3.5)
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A total of 759 patients with DME were randomized to sham or 1 of
the 2 active ranibizumab treatment arms. Baseline fundus photo-
graphs were available for 746 patients, of which 739 (97%) could
be evaluated. The number of study eyes with HE at baseline was
similar across all groups: 200 (79.1%) in the sham group, 187
(77.9%) in the 0.3-mg ranibizumab group, and 188 (76.4%) in the
0.5-mg ranibizumab group. The mean area  standard error of HE
at baseline was 0.820.06, 0.650.06, and 0.680.06 mm2 for the
sham, 0.3-mg ranibizumab, and 0.5-mg ranibizumab groups,
respectively. The approximately 0.1-mm2 difference in mean HE
area across the groups is too small to be relevant in the scheme of
the classiﬁcation, considering the magnitude of the differences in
HE severity categories and the range of areas observed. At base-
line, the distribution of ETDRS classiﬁcation of HE also was
similar in the 3 groups (Table 1).
Over time, resolution of HE area was signiﬁcantly more com-
mon in the ranibizumab-treated groups, although some improve-
ment of HE area was observed in the sham group as well (Fig 2). A
difference in the presence of HE between the sham and
ranibizumab-treated groups was evident at month 12, with
approximately 40% to 43% of ranibizumab-treated eyes having no
HE compared with 26% of eyes in the sham injection group.
Through 24 months, the percentage of study eyes in the HE absent
category increased from 20.9% to 36.3% in the sham arm and from
22.1% to 61.3% and 23.6% to 62.0% in the 0.3- and 0.5-mg253 221 20
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Figure 2. Bar graph showing resolution of hard exudate (HE) occurring over t
present.ranibizumab arms, respectively. Thus, more than 60% of
ranibizumab-treated eyes experienced complete resolution of HE
compared with 36% of eyes in the sham group (P < 0.0001).
Figure 3 shows a cross-tabulation between HE category at
baseline compared with the category at month 24. Hard exudate
area improved in most eyes, with a higher proportion of patients
demonstrating a 2-step improvement (e.g., HE area reduction from
moderate [>0.5e2.5 mm2] to deﬁnite [>0e0.1 mm2]) in the
ranibizumab arms compared with sham. At month 24, a 2-step
improvement in HE category occurred in 24% of eyes in the
sham group and 39% in the 2 ranibizumab treatment arms
(P ¼ 0.001, chi-square test). In eyes with severe HE at baseline
(n ¼ 21), 11 eyes treated with ranibizumab demonstrated a 2-step
or more improvement in HE category compared with 3 eyes in the
sham arm.
There was no correlation between baseline visual acuity and the
total area of HE in any of the 3 treatment groups (Fig 4); Pearson
correlation coefﬁcients were 0.16 (sham), 0.01 (0.3 mg
ranibizumab), and 0.18 (0.5 mg ranibizumab). The presence of
central HE (i.e., in the center of the fovea) also was not
correlated meaningfully with baseline visual acuity (Pearson
correlation coefﬁcient, 0.1153; P ¼ 0.0056).
Figure 5 shows the change over time in visual acuity in patients
in the ranibizumab and sham groups, categorized according to the
status of central HE at baseline. In the ranibizumab groups, eyes
with central HE at baseline seemed to trend toward greater
improvements in visual acuity compared to eyes without central6 200 191 190
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Figure 3. Early treatment diabetic retinopathy study categorization of hard exudate at baseline and at 24 months. The ﬁgure shows the percentage of eyes in
each category at 24 months. Dark gray boxes indicate 2-step improvement of hard exudate categorization from baseline, bounded gray boxes indicate no
change from baseline, and light gray boxes show the percentage of eyes with 2-step worsening of hard exudate category. Hard exudate severity
categories were deﬁned according to Early Treatment Diabetic Retinopathy Study criteria as absent (no hard exudate present), deﬁnite (>0-0.1 mm2),
obvious (>0.1-0.5 mm2), moderate (>0.5-2.5 mm2), and severe (>2.5 mm2).
Ophthalmology Volume 122, Number 4, April 2015HE. However, the trend was statistically signiﬁcant in the 0.3-mg
ranibizumab arm only.
In patients randomly assigned to sham injections, mean
improvements in OCT central foveal thickness from baseline after
24 months were statistically signiﬁcantly greater in patients with
HEs present at baseline (109.41 vs. 82.25 mm; P ¼ 0.0231).
The mean reduction in OCT central foveal thickness from baseline
at month 24 was not statistically different in eyes with or without
baseline HE in patients treated with 0.3 or 0.5 mg ranibizumab
(P ¼ 0.3779 and P ¼ 0.6041, respectively; Table 2, available
online at www.aaojournal.org).
To validate further the HE grading metric used in this report,
repeat grading was performed on 117 eyes. Intergrader concor-
dance was 92.5% in the 1-step improvement group and 99.6% in
the 2-step group on the ordinal scale, with a weighted k of 0.73
(95% conﬁdence interval, 0.7e0.77). Intraclass correlation coefﬁ-
cient for the area measurement was 0.87, with a mean difference of
0.04 mm2 (95% conﬁdence interval, 0.71 to 0.63).
Discussion
Monthly intravitreal ranibizumab has a beneﬁcial effect on
reduction of HE area, as shown in this exploratory analysis782from phase III randomized clinical trials in patients with
DME. Most eyes (>75%) had HE at baseline. There was a
signiﬁcant resolution of HE in more than 60% of eyes in the
ranibizumab groups compared with only 36% in the sham
group at the end of the 24-month follow-up period. Very
few eyes in any treatment group had a worsening of HE at
any time during the study.
It has been hypothesized previously that treatment for
DME (with laser photocoagulation, for example) can leave
residual HE as an extracellular precipitate within the retina
as the macular edema resolves.25,26 In contrast, the current
study shows that neither the presence nor overall area of HE
increases as DME resolves. This was observed across all
treatment groups. Note that approximately 72% of patients
in the sham group received macular laser treatment during
the RIDE and RISE studies.22 Images were obtained at
baseline and every 3 to 6 months thereafter, so it is
possible, but unlikely, that the hypothesized phenomenon
of increased HE coinciding with edema resolution could
have occurred within this duration and was missed
because of the timing of image capture. This is unlikely
Figure 4. Scatterplot showing baseline visual acuity versus baseline total area of hard exudate (HE) in the study eye by baseline center HE status. Horizontal
rules are trendlines. ETDRS ¼ Early Treatment Diabetic Retinopathy Study; VA ¼ visual acuity.
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initial 3-month period and then decrease again to baseline
levels because the area of HE was very similar at baseline
and month 3. A detailed examination of the categorical shift
in HE over time shows that the resolution of HE in both
ranibizumab arms is not evident before 6 months of treat-
ment. In contrast, the RIDE and RISE trials showed that
resolution of edema and improvement in vision in the
ranibizumab group started as early as day 7 after the ﬁrst
intravitreal treatment.22 This supports the conclusion that
macular edema is the ﬁrst to resolve, followed by a later
resolution of HE.
The presence of HE has been considered to be a sign of
recalcitrant macular edema with worse prognosis for visual
recovery. Chew et al6 demonstrated that after adjustment for
extent of macular edema, HE represented a signiﬁcant risk
factor for poor visual outcome in the ETDRS. In the
current data set, there was almost no correlation between
visual acuity outcomes and the presence or absence of HE
at baseline; a similar lack of correlation was observed
when considering both the total area of HE at baseline
and also the presence or absence of HE at the fovea.
Indeed, there was a general trend toward better visual
acuity outcomes for those with HE at the center of the
fovea at baseline compared with those without HE, for
both the ranibizumab and sham groups. Of note, the
baseline visual acuity measurements were very similar, so
the trend is not likely inﬂuenced by ﬂoor or ceiling effects
in visual acuity change.27 The severity of HE in this study
is probably lower than that in ETDRS participants because
of better systemic diabetes control in this contemporary
cohort, with most eyes in the RIDE and RISE studies in
the obvious or moderate categories (<2.5 mm2 or 1 disc
area). The number of eyes in the severe category was too
small to assess visual prognosis, and the number of
patients in the ranibizumab groups who lost 15 or more
ETDRS letters of VA also was very small.22 Severe HEdid not exclude patients from participation in RIDE or
RISE; however, patients with this level of HE severity
may have been excluded based on visual acuity criteria.
Better regulation of serum cholesterol and other systemic
factors in the current cohort compared with patients
enrolled in the ETDRS study also could be a possible
reason for the overall lower severity of HE in the current
cohort.
In an assessment of pooled treatment groups of the Dia-
betic Retinopathy Clinical Research Network Protocol I
interventional study of DME, Bressler et al28 showed that the
presence of retinal HE seen on color photographs was
associated with more favorable OCT outcomes (i.e., better
reduction in thickness) after adjusting for baseline central
subﬁeld thickness. The authors hypothesized that presence
of HE may indicate retinal microvascular hyperpermeability
as the pathological mechanism for edema, which is
amenable to the pharmacologic inhibition of VEGF with
ranibizumab. Hard exudates could be indicative of a
nonischemic process and therefore could respond to anti-
VEGF therapy. In the RIDE and RISE studies, although
eyes with HE at the center trended toward larger gains in
visual acuity from baseline, no statistically signiﬁcant dif-
ferences in visual gain or central retinal thickness change
were observed in patients who did or did not have exudate at
the center before starting treatment with ranibizumab. By
contrast, eyes in the sham injection group with HE present at
baseline demonstrated a signiﬁcantly greater reduction in
central retinal thickness after 24 months of observation (plus
macular laser in approximately 75% of patients), compared
with eyes having no HE at baseline. Other possible mecha-
nisms of action are direct effect29 and clearance by
phagocytic inﬂammatory cells such as macrophages.30
The main weakness of the current study is the explor-
atory (post hoc) nature of the analysis. The RIDE and
RISE phase III studies primarily were designed to evaluate
the efﬁcacy of ranibizumab on visual acuity, not the effect783
AB
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Figure 5. Graphs showing study eye mean visual acuity (VA) change from baseline by the presence and absence of hard exudate (HE) in the center subﬁeld
in patients receiving (A) sham injections, (B) monthly 0.3 mg ranibizumab, and (C) monthly 0.5 mg ranibizumab. Lines correspond to baseline best-
corrected VA in eyes with (black) and without (gray) HE in the center or inner subﬁelds at baseline. Bars represent 95% conﬁdence intervals.
ETDRS ¼ Early Treatment Diabetic Retinopathy Study.
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However, there are several strengths to the current anal-
ysis. These include the relatively large number of eyes
with evaluable photographs (739 eyes total between the 2
studies) and the fact that the distribution of HE area was784similar in the 3 treatment arms at baseline. Additionally,
the fundus photographs were obtained by certiﬁed pho-
tographers, obtained serially at protocol-prescribed
intervals throughout the 24-month study period, and
evaluated by trained and masked evaluators at an
Domalpally et al  Ranibizumab for Retinal Hard Exudate in DMEindependent reading center with speciﬁc expertise in dia-
betic retinopathy imaging. Finally, the cohort studied is
one of a very few with exposure to monthly ranibizumab
for 24 months. This allows for an assessment of the effect
of anti-VEGF therapy with ranibizumab on area of HE in
the absence of potentially confounding circumstances,
such as adherence to a re-treatment protocol, or conco-
mitant use of other therapies, such as corticosteroids or
other anti-VEGF drugs.
In conclusion, monthly intravitreal ranibizumab results
in a signiﬁcant reduction of the area of HE compared with
sham therapy, rescue macular laser, or both. The effect was
profound, with most eyes treated with ranibizumab having
an absence of HE at the end of the study period. In contrast
to the rapid effect of ranibizumab on visual acuity and
retinal thickness, the effect of ranibizumab on HE area
seems to be more gradual, with a detectable effect no
earlier than 6 months after treatment is initiated. In the
current study, baseline HE was not meaningfully correlated
with baseline visual acuity or with change in visual acuity
after treatment with ranibizumab, although those with
central HE at baseline trended toward better visual acuity
outcomes. These ﬁndings suggest that in eyes with
concomitant DME and moderate areas of HE at baseline, it
can be expected that the area of HE will be reduced
gradually with ranibizumab therapy. Importantly, the use of
ranibizumab should not be discouraged in eyes with HE at
baseline because the presence of HE does not predict an
inferior visual outcome compared with eyes that do not
have HE at presentation.
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